Endocrine-disrupting chemicals, or EDCs, are synthetic compounds that can mimic, block or scramble hormonal signaling. They are woven into modern life almost invisibly: bisphenol A (BPA) leaches from polycarbonate plastics, epoxy-can linings and thermal receipt paper; perfluorooctanoic acid (PFOA) belongs to the sprawling family of per- and polyfluoroalkyl substances, or PFAS, long used in nonstick cookware, water-repellent textiles and firefighting foams; di(2-ethylhexyl) phthalate (DEHP) softens vinyl products and medical tubing; the flame retardant BDE-209 sheds from consumer goods into household dust; the pesticide DDT, banned in most countries decades ago, persists in soils and fatty tissue; and the dioxin TCDD, an industrial byproduct, ranks among the most potent synthetic toxins ever characterized. Because the thyroid gland depends on precisely tuned hormonal feedback to regulate metabolism, growth and development, it is considered acutely vulnerable to such exposures. Global burden analyses have documented a steep, decades-long rise in thyroid cancer incidence, and while improved detection explains part of the trend, environmental contributors remain a live scientific concern. Epidemiological studies have linked several of these chemicals to thyroid dysfunction, nodules and cancer risk, yet the molecular steps that turn exposure into tumor progression have remained stubbornly opaque—precisely the gap the new study set out to close.

The Wuhan-led team began not at the laboratory bench but at the computer. They first ran all six chemicals—BPA, PFOA, DDT, BDE-209, TCDD and DEHP—through ADMETlab 3.0, a machine-learning web platform that predicts a compound’s absorption, distribution, metabolism, excretion and toxicity directly from its molecular structure, providing a standardized read on how hazardous each molecule is likely to be. They then mined the Comparative Toxicogenomics Database, a curated public repository that logs which genes have been experimentally shown to respond to which chemicals. In parallel, the researchers compiled lists of genes implicated in thyroid cancer from multiple disease databases. Overlaying the chemical-response gene sets with the cancer gene sets produced a shared space of 1,113 EDC–thyroid cancer targets: genes that both respond to endocrine-disrupting chemicals and participate in malignant thyroid disease.

To give that list biological meaning, the team performed pathway enrichment analysis, a statistical method that tests whether a set of genes clusters within particular signaling networks more densely than chance would predict. The 1,113 shared targets concentrated strikingly in three circuits. The PI3K–Akt pathway, a core growth-control cascade promoting cell survival, proliferation and metabolism, is among the most frequently dysregulated networks in human cancer. The FoxO transcription factor family acts downstream of Akt and governs cell-cycle arrest, DNA repair, apoptosis and oxidative-stress resistance—functions of special relevance in the thyroid, where hormone synthesis inherently generates reactive oxygen species. The AGE–RAGE axis, which couples advanced glycation end products to their cell-surface receptor RAGE, sustains chronic inflammatory signaling and has previously been implicated in the migratory behavior of thyroid cancer cells. Convergence of EDC-responsive genes on these pro-growth, pro-survival, pro-inflammatory circuits handed the researchers their first mechanistic hypothesis: chemical exposure may be rewiring the very pathways that decide whether a thyroid tumor grows, spreads or dies.

The next question was which of those 1,113 genes actually separate tumor tissue from healthy thyroid. Differential expression analysis of transcriptomic datasets filtered the candidates down to genes consistently dysregulated in cancer, and the shortlist then went to machine learning. The team applied least absolute shrinkage and selection operator (Lasso) regression, an algorithm that penalizes model complexity and drives the coefficients of uninformative genes to exactly zero, compressing hundreds of features into a minimal signature. The surviving genes were classified with linear discriminant analysis (LDA), a supervised method that separates patient groups along an optimal linear boundary. The resulting six-gene diagnostic model—FN1, which encodes the extracellular-matrix protein fibronectin; BCL2, a canonical anti-apoptotic gene; CD44; CDKN1A, which encodes the cell-cycle brake p21; CTNNB1, the gene for β-catenin at the core of WNT signaling; and JUN, a pillar of the AP-1 transcription factor—achieved an average area under the receiver operating characteristic curve (AUC) of 0.976 across a training cohort and three independent validation cohorts. An AUC of 1.0 signifies perfect discrimination and 0.5 mere coin-flipping, so a value nearing 0.98 represents diagnostic performance close to clinical grade.

Within that six-gene panel, one name kept rising to the top. Evaluated alone, CD44 achieved AUC values of 0.950 in the training set, 0.801 in the external dataset GSE27155, 0.878 in GSE29265 and 0.938 in GSE153659—performance that persisted across cohorts generated by different laboratories on different platforms, a robustness that matters because datasets built independently are far less likely to share hidden technical biases. To understand why the algorithm leaned so heavily on this gene, the researchers deployed SHAP analysis, short for SHapley Additive exPlanations, a game-theoretic framework borrowed from economics that distributes the credit for every prediction among the features that produced it. In the SHAP ranking, CD44 made the largest single contribution to the model’s output, evidence that the machine had not latched onto a statistical artifact but onto the gene that best captured the boundary between tumor and healthy tissue.

CD44 is no obscure molecule. It encodes a transmembrane glycoprotein that serves as the principal cell-surface receptor for hyaluronic acid, the gel-like polymer filling the space between cells, and through that interaction it governs adhesion, migration and invasion. It is a defining marker of cancer stem cells—the self-renewing subpopulation thought to seed relapse and shrug off therapy—and has been tied to progression and metastasis across many tumor types, including papillary thyroid carcinoma. The new study layered further dimensions onto that profile. Immune infiltration analysis indicated that CD44 expression covaries with the makeup of the tumor immune microenvironment, the mix of macrophages, T cells and other immune players surrounding a growing tumor. Survival analysis of data from The Cancer Genome Atlas linked CD44 levels to patient prognosis, and single-cell RNA sequencing positioned the gene as a marker of shifting cellular states within malignant cells. Taken together, these analyses cast CD44 as sitting at the junction where environmental stress, tumor identity and immune context meet.

The most provocative question was whether the chemicals themselves can physically engage CD44. To probe it, the team used molecular docking, a computational technique that fits flexible small molecules into the three-dimensional structure of a protein’s binding region and scores how well each one lodges there. Docking produced plausible binding poses for BPA, DEHP and PFOA on CD44, with PFOA—the eight-carbon fluorinated compound infamous for its nearly unbreakable carbon–fluorine backbone—returning the most favorable predicted docking score. The researchers then stress-tested each protein–ligand complex with 200-nanosecond molecular dynamics simulations, which track every atom of the pair in a simulated water environment and reveal whether an interaction holds together or falls apart over realistic molecular timescales. The complexes remained plausible across the simulated run, supporting—though not yet proving—direct physical contact between these environmental chemicals and the CD44 protein. The authors are careful with language here: docking scores and simulated stability are computational hypotheses that will need confirmation by direct biophysical measurements such as surface plasmon resonance or calorimetry.

Computational hypotheses were not the endpoint. In the laboratory, the team confirmed that CD44 is expressed at higher levels in thyroid cancer tissues and thyroid cancer cell lines than in normal counterparts. When the cells were exposed to endocrine-disrupting chemicals, CD44 expression climbed further. The decisive experiment followed: using molecular tools to knock down CD44—silencing the gene so its protein is no longer made—the researchers showed that the gains in proliferation, colony formation and migration that ordinarily follow EDC exposure were substantially attenuated. Colony-forming assays, which measure how many single cells can found entire colonies, and migration assays, which track how quickly cells close a wound-like gap or invade through a membrane, are standard readouts of malignant potential. In effect, the experiment closed a loop: chemical exposure raises CD44, elevated CD44 licenses aggressive behavior, and removing CD44 strips much of that behavior away.

The authors frame CD44 as a candidate target associated with EDC-responsive malignant phenotypes in thyroid cancer—a deliberately measured formulation that reflects both the strength and the limits of the evidence. The study does not claim that endocrine-disrupting chemicals initiate thyroid cancer, and a docking score is not a demonstrated drug-like interaction. What it does establish is a coherent, multi-layered chain of evidence: computational toxicity profiling, toxicogenomic mining, pathway convergence, a near-clinically accurate six-gene diagnostic model, single-gene robustness across independent cohorts, microenvironmental and single-cell corroboration, structural simulation, and finally laboratory intervention. If future work confirms direct CD44 binding by these chemicals in living systems and validates the diagnostic panel in prospective patient cohorts, the implications are considerable, because CD44 is already pursued as an oncology target through antibodies and hyaluronan-based drug delivery strategies, offering a plausible road from biomarker to intervention. In the meantime, the study adds molecular weight to a public-health argument that has been building for years: curbing exposure to endocrine-disrupting chemicals is not merely an endocrine issue—it may be an oncological one.

The human gut microbiome has long been recognized as a critical player in health and disease, but the enzymatic activities of specific bacterial populations remain an intricate puzzle. β-glucuronidases, a class of enzymes produced by various gut microbes, catalyze the hydrolysis of glucuronides, a key metabolic step in the recycling of compounds within the gastrointestinal tract. This enzymatic action can significantly alter the bioavailability of many metabolites, including drugs, hormones, and dietary compounds, which in turn influence cellular processes in the colon.

Chen, Li, Tang, and their colleagues conducted a meticulous characterization of gut microbial β-glucuronidase activity in colorectal cancer patients compared to healthy controls. Their multi-omics approach incorporated metagenomics, metabolomics, and enzyme assays, unveiling distinct profiles of β-glucuronidase-producing bacteria associated with tumor microenvironments. Notably, they identified an enrichment of β-glucuronidase activity in malignant tissues, suggesting these enzymes contribute directly to oncogenic metabolic pathways.

One of the pivotal insights from this study is the link between β-glucuronidase activity and reactivation of glucuronidated metabolites, which are typically destined for excretion. Reactivated metabolites can induce DNA damage, promote inflammation, and perturb cellular signaling cascades, thereby creating a microenvironment conducive to tumor development. This mechanism challenges the prevailing notion that microbial contributions to colorectal cancer are merely correlative, positioning β-glucuronidases as causative agents in metabolic dysregulation.

Furthermore, this work elaborates on how β-glucuronidases intersect with drug metabolism, notably impacting chemotherapeutic agents used in colorectal cancer treatment. Reactivation of drug glucuronides within the gut can modulate drug efficacy and toxicity, potentially explaining variations in patient responses. The authors advocate for personalized medicine approaches that consider an individual’s gut microbial β-glucuronidase profile to optimize therapeutic regimens and minimize adverse effects.

The team also explored the structural diversity of β-glucuronidase enzymes among different bacterial taxa. Structural analyses revealed unique catalytic motifs and substrate specificities that influence how these enzymes interact with diverse glucuronidated compounds. By mapping these variations, the researchers paved the way for selective enzyme inhibitors that could strategically suppress harmful β-glucuronidase activity without disrupting beneficial microbial functions.

One of the most remarkable aspects of this research is the elucidation of the microbiome-metabolite axis as a dynamic and bidirectional system. β-glucuronidases do not merely modify metabolites; they modulate signaling pathways that reciprocally influence microbial community composition. This feedback loop can amplify pathogenic states or restore homeostasis, depending on contextual factors like diet, inflammation, and genetic predispositions.

The significance of these findings extends beyond colorectal cancer. Since β-glucuronidases are widespread in the gut microbiome, their impact on systemic metabolite profiles could implicate them in a variety of diseases linked to metabolic dysregulation, including liver disorders, hormonal diseases, and inflammatory bowel disease. The researchers propose investigating whether targeted modulation of β-glucuronidase activity might serve as a therapeutic modality in these conditions.

Moreover, the study’s integrative methodology stands out as a model for future microbiome research. Combining high-resolution sequencing with functional enzymatic data and metabolite profiling allows for a holistic view of how microbial communities influence host health at a molecular level. This approach transcends simple microbial cataloging and shifts focus towards mechanistic insights that can inspire translational applications.

To validate their findings, the authors utilized in vitro and in vivo models demonstrating that pharmacological inhibition of β-glucuronidases led to significant reductions in tumor burden and inflammation markers. These experimental results underscore the translational potential of targeting microbial enzymes to interfere with disease progression. Promisingly, the development of small-molecule inhibitors that selectively inhibit these microbial β-glucuronidases is underway, aiming to complement existing cancer therapies.

The therapeutic implications of this research are profound. Precision microbiome editing strategies, including phage therapy and CRISPR-based microbial gene editing, could be harnessed to diminish deleterious β-glucuronidase-producing bacterial populations. Such approaches would augment conventional treatments and potentially reduce recurrence rates by addressing the microbial underpinnings of colorectal cancer.

Importantly, the research highlights the necessity of individualized microbiome assessment in clinical settings. Given the inter-individual variability in microbial β-glucuronidase gene content and activity, patient-specific profiles could become critical biomarkers not only for cancer risk assessment but also for monitoring treatment response and guiding dietary recommendations aimed at modulating microbiome function.

This pioneering work also underscores the role of gut microbial enzymes as gatekeepers of host metabolic networks. Future investigations are anticipated to explore the broader enzymatic repertoire of the microbiome, mapping additional metabolic pathways that intersect with host physiology and disease. The interplay between microbial enzyme activity and host epigenetic modifications represents an exciting frontier inspired by these findings.

In conclusion, the study by Chen and colleagues propels the field of microbiome research into a new era where enzymatic functions within microbial communities are dissected for their roles in cancer biology. This paradigm shift from microbial presence to microbial function provides a more nuanced understanding of colorectal carcinogenesis and unveils promising targets for precise interventions. As research continues to bridge microbiology, metabolism, and oncology, the gut microbiome’s enzymatic landscape emerges as a critical determinant of health and disease.

Ultimately, embracing the complex landscape of gut microbial β-glucuronidases offers transformative potential for colorectal cancer diagnosis, therapeutic innovation, and personalized healthcare. This landmark study lays a comprehensive foundation upon which future research and clinical strategies will undoubtedly build, redefining how we interpret and manipulate the microbiome-metabolite axis to combat cancer.

Subject of Research:
Gut microbial β-glucuronidases and their impact on colorectal cancer through modulation of the microbiome-metabolite axis.

Article Title:
Gut microbial β-glucuronidases and their role in the microbiome-metabolite axis in colorectal cancer.

Article References:
Chen, J., Li, Y., Tang, S. et al. Gut microbial β-glucuronidases and their role in the microbiome-metabolite axis in colorectal cancer. Nat Commun 16, 10660 (2025). https://doi.org/10.1038/s41467-025-65679-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65679-y